Deutsches Krebsforschungszentrum

Ruprecht-karls-universitat Heidelberg

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts and Ruprecht-karls-univeristat Heidelberg

Ruprecht-karl-universität Heidelberg

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Andreas Von Deimling

Hanswalter Zentgraf

David Capper

Hartmut Rehwinkel

Katja Zimmermann

Wolfgang Schwede

Duy Nguyen

Sven Ring

Roland Neuhaus

Marcus Bauser

Sonja Anlauf

Olaf Panknin

Holger Siebeneicher

Wolfgang Buckel

Stefan Kaulfuss

Wolfgang Wick

David Jones

Michael Weller

Guido Reifenberger

Christian Hartmann

Stefan Pusch

Jörg Balss

Martin Sill

Melanie Bewerunge-hudler

Stefan Pfister

The present invention relates to a method for detecting (D)-2-hydroxyglutarate or (D)-2-hydroxyadipic acid in a sample, the method comprising the steps of: a) contacting a sample with a reagent mixture, wherein said reagent mixture comprises: (i) a solvent, (ii) a dye having an oxidized state and a reduced state, wherein the reduced state can be distinguished from the oxidized state and wherein the dye is initially present in the oxidized state, (iii) an electron transfer agent, (iv) a (D)-2-hydroxyglutarate dehydrogenase enzyme, and (v) a cofactor; and b) detecting (D)-2-hydroxyglutarate or (D)-2-hydroxyadipic acid by measuring the production of the reduced state of the dye. The invention further pertains to a method for diagnosing and/or monitoring a (D)-2-hydroxy-glutarate-associated disease in a subject. Encompassed by the invention is also a method for diagnosing a mutation in an isocitrate dehydrogenase (IDH) gene or in a (D)-2-hydroxyglutarate (D2HG) dehydrogenase enzyme gene in a subject. In addition, the invention provides for a kit comprising (i) a solvent, (ii) a dye having an oxidized state and a reduced state, wherein the reduced state can be distinguished from the oxidized state and wherein the dye is initially present in the oxidized state, (iii) an electron transfer agent, (iv) a (D)-2-hydroxyglutarate dehydrogenase enzyme, and (v) a cofactor.

Means and methods for the determination of (D)-2-hydroxyglutarate (D2HG) or (D)-2-hydroxyadipic acid

The present invention relates to the field of diagnostic tests and diagnostic tools. Specifically, contemplated is to a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer comprising contacting the sample with an antibody which specifically binds to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide under conditions which allow for binding of said antibody to the epitope and determining binding of the antibody to the epitope, whereby cancer is diagnosed. Further contemplated are antibodies which specifically bind to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide and a device or kit comprising such antibodies.

Means and methods for diagnosing cancer using an antibody which specifically binds to BRAF V600E

The present invention relates to methods for the diagnosis of a brain tumor and for the estimation of a prognosis for patients having a brain tumor using the presence/absence of a particular IDH1 mutation as a marker.

Methods for the diagnosis and the prognosis of a brain tumor

Growing community of inventors

Schriesheim, Germany

Andreas Von Deimling